Anthropic Makes Drugs While AI Chips Empty Your Wallet

Here is a fact that would have sounded absurd two years ago: one of the most powerful AI labs in the world just announced it plans to develop its own pharmaceutical drugs.

Anthropic made the declaration this week at an event called "The Briefing: AI for Science," where it also unveiled Claude Science — a new platform designed to give researchers a single environment to work with fragmented tools, datasets, and scientific literature. The product generated figures, visualizations, and analysis in one place. That part alone was notable. But the drug development announcement was something else entirely.

Eric Kauderer-Abrams, Anthropic's head of life sciences, said the company would focus its drug discovery efforts on so-called neglected diseases — conditions that tend to get overlooked by Big Pharma because the financial return isn't there. It's a smart framing. Positioning yourself as the company that goes after diseases nobody else will tackle makes for a compelling story. But Anthropic offered almost no specifics about what that actually looks like in practice.

What diseases are they targeting first? Will they partner with labs for animal testing or clinical trials? What happens if they find a promising drug candidate? Anthropic didn't answer any of these questions, even when pressed. That silence is worth noting, not to be cynical, but because the gap between "we will develop drugs" and "here is a drug" is enormous and littered with failed attempts by well-funded organizations.

Still, the ambition matters. Anthropic is arguably the first major frontier AI company to publicly commit to developing drugs itself, not just selling tools to companies that do. That creates a genuinely strange dynamic: Anthropic now sells software to pharma companies while simultaneously competing with them in the lab. It is the kind of vertical move that would raise eyebrows in any industry.

The broader context here is that every major tech company is chasing the life sciences market right now. OpenAI, Google, Amazon — they all have platforms aimed at biotech and pharma customers. AI-first drug companies like Insilico and Isomorphic Labs, spun out of Google DeepMind, are further along in actual drug pipelines. Anthropic is entering a crowded and complicated space.

Experts who study this area are quick to point out that "AI drug discovery" is less a specific thing and more an umbrella term covering everything from identifying new molecular compounds to running clinical trial data analysis. AI already touches nearly every stage of the process. The question is not whether AI belongs in drug development — it clearly does — but whether any of these tools will produce treatments that actually reach patients at scale.

That last part is the hard part. The history of drug development is a graveyard of promising science that collapsed somewhere between discovery and approval. Anthropic's ambitions are genuinely interesting. Now comes the part where ambition has to meet biology.

If you have been putting off buying a laptop, a phone, or a gaming console, the advice from people who track this stuff professionally is pretty blunt: stop waiting.

A fresh wave of price increases is rolling through consumer electronics, and the root cause is not tariffs or shipping costs or inflation in the traditional sense. It is artificial intelligence. Specifically, the insatiable demand for memory chips from AI data centers has created a supply squeeze that is now rippling out to every device that needs those same components. Which is basically every device.

Apple raised prices on MacBooks and iPads in June. Xbox consoles are getting more expensive starting in August. Sony's PlayStation 5 Pro already saw price adjustments. These are not small companies absorbing temporary disruptions — these are signals that the shortage is structural and that manufacturers have decided they cannot keep eating the cost.

Shawn DuBravac, chief economist at the Global Electronics Association, put it plainly: waiting is not a strategy right now, and it probably will not be for the foreseeable future. In past chip crunches, patient consumers could ride out the turbulence. This one is different because the underlying driver — AI infrastructure buildout — shows no signs of slowing down. Data center operators keep buying chips in massive quantities, which means consumer electronics manufacturers keep getting pushed to the back of the line.

The math is straightforward and uncomfortable. When demand outpaces supply for an extended period, companies pass the cost to consumers. What makes this round particularly frustrating is the timing. Back-to-school season is approaching, and holiday product cycles are not far behind. Families who were planning to replace a laptop or pick up a new phone for a kid heading to college are now making those decisions in a more expensive environment than they expected.

There is a silver lining, though it requires a small shift in thinking. The refurbished and secondhand electronics market is genuinely booming right now, and experts say it has never been a better time to buy used. Refurbished devices are cheaper, often come with warranties through reputable sellers, and are objectively better for the environment than buying new. Platforms and recommerce companies that specialize in used smartphones and laptops are seeing surging demand, which means inventory is relatively healthy.

For people who absolutely need something new, the guidance from analysts is to buy sooner rather than later if that item has not yet seen a price increase — because it likely will. And if something has already gone up in price, you may actually have a small window to think it over before the next round of increases hits.

The uncomfortable reality is that the AI boom has costs that extend well beyond data centers and server farms. One of them shows up on the price tag of your next phone.